Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 13Phase 1/2 10Phase 3 6Phase NA 2Phase 4 1

Status

Completed 2Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Breast 3

Conditions

Breast Neoplasms 119HER2-positive Breast Cancer 10Stomach Neoplasms 9Neoplasm Metastasis 6Neoplasms 4Inflammatory Breast Neoplasms 4Esophageal Neoplasms 3Adenocarcinoma Of Esophagus 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Invasive Breast Cancer 2HER2-positive Metastatic Breast Cancer 2HER2-positive Early Breast Cancer 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Solid Tumors 1Resectable HER2-positive Breast Cancer 1Patient Preference 1Pathologic Complete Response 1Osteitis Deformans 1Metastatic HER2-positive Breast Cancer 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Gastric Cancer 1HER2-positive Carcinoma of Breast 1HER2-positive Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Early or Locally Advanced Breast Cancer 1HER2 Positive Early Breast Cancer 1Endometrial Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

Leucovorin 22Fluorouracil 22Gemcitabine 21Capecitabine 21Paclitaxel 20Docetaxel 20Irinotecan 15Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × Trastuzumab × Clear all
NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT01613482 2026-03-16

TSARINE

Centre Oscar Lambret

Phase 3 Terminated
13 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02492711 2025-03-17

SOPHIA

MacroGenics

Phase 3 Completed
624 enrolled 17 charts 1 FDA
Tumor-Agnostic

Neoplasm Metastasis

NCT03811418 2019-11-26

ATTILA

iOMEDICO AG

Phase 3 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT00876395 2018-12-19

BOLERO-1

Novartis

Phase 3 Completed
719 enrolled 25 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00637325 2008-03-17

TOP

Regione Lombardia

Phase 3 Unknown
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡